Status:
UNKNOWN
CERebrolysine Effect on Blood-brain Barrier in acUte Ischemic Stroke
Lead Sponsor:
Poznan University of Medical Sciences
Conditions:
Acute Ischemic Stroke
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
The study investigates whether Cerebrolysin stabilizes blood-brain barrier integrity in a manner that can be monitored using serum levels of the principal tight junction proteins, e.g., occludin (OCL)...
Detailed Description
Hemorrhagic transformation (HT) of ischemic stroke can be identified in 3-40% of patients. The incidence varies depending on the definition used and the studied population. The severity of HT can be d...
Eligibility Criteria
Inclusion
- acute ischemic stroke patients
- informed consent
Exclusion
- no informed consent
- primary or metastatic brain tumor
- brain abscess
- encephalitis
- localized inflammation
- sepsis
- autoimmune diseases of central or peripheral nervous system
- Cerebrolysin hypersensitivity / allergy
- epilepsy
- severe kidney disease
Key Trial Info
Start Date :
January 10 2023
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
March 31 2025
Estimated Enrollment :
350 Patients enrolled
Trial Details
Trial ID
NCT06078215
Start Date
January 10 2023
End Date
March 31 2025
Last Update
October 13 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University Hospital
Poznan, Poland, 60-355